News
Potent Impact on Colorectal Liver Metastasis: In an experimental liver metastatic model of colorectal carcinoma (CT26 Luc), Annamycin significantly inhibited metastatic growth and extended survival, ...
Anbogen Therapeutics gains FDA approval for ABT-301, initiating a pivotal trial for metastatic colorectal cancer, targeting ...
GlobalData on MSN2d
FDA approves Anbogen’s ABT-301 trial for metastatic colorectal cancer
The US Food and Drug Administration (FDA) has approved Anbogen Therapeutics’ investigational new drug (IND) application for ...
HealthDay on MSN1d
Rise in colon cancer cases attributed to lower screening age
The American Cancer Society says an uptick in colon cancer cases in the 45-49 age group is a result of lowered screening ages ...
Key Takeaways Zanzalintinib plus atezolizumab showed significant survival benefits over regorafenib in non-MSI-high metastatic colorectal cancer patients in the STELLAR-303 trial. The trial's safety ...
The Phase I/II trial will evaluate the safety and early efficacy of ABT-301 in combination with tislelizumab and bevacizumab ...
Key Takeaways Leronlimab demonstrated partial or complete responses in advanced metastatic colorectal cancer, supporting its potential in solid tumor oncology. Increased PD-L1 expression in ...
More information: Mariola Monika Golas et al, Cytogenetic signatures favoring metastatic organotropism in colorectal cancer, Nature Communications (2025). DOI: 10.1038/s41467-025-58413-1 ...
Dasari NA, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study [published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback